Genmab improves financial guidance on new FDA Darzalex nod

The US Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Darzalex is being developed by Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), under an exclusive worldwide license to develop, manufacture and commercialize the treatment from Genmab (OMX: GEN), shares of which were 2.4% higher as Tuesday’s trading entered its final third.

"We believe daratumumab has the potential to become a backbone therapy for multiple myeloma"